[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"avascular-necrosis-of-hip\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:avascular-necrosis-of-hip":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100466718","safety-and-effectiveness-of-the-hit-reverse-hrs-100466718",false,"NCT05357378","Safety and Effectiveness of the HIT Reverse HRS","Safety and Effectiveness of the Hip Innovation Technology Reverse Hip Replacement System in Primary Total Hip Arthroplasty: A Pivotal Study","Inclusion Criteria:\n\n* Patient requires primary THA due to NIDJD or any of its composite diagnoses such as osteoarthritis, avascular necrosis, posttraumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary THA.\n* Patient is between 50 (inclusive) and 75 (inclusive) years of age at the time of enrollment.\n* Patient has preoperative medical clearance and is free from or treated for medical conditions that would pose excessive operative risk.\n* Patient has a signed and dated Informed Consent Form (ICF).\n* Patient is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires.\n\nExclusion Criteria:\n\n* Patient has received earlier THA, hemi-arthroplasty, or fusion in the contralateral hip in the last 24 months.\n* Patient has received earlier THA, hemi-arthroplasty, or fusion in the contralateral hip more than 24 months ago and has a contralateral hip-specific pain rating of ≥2 on a Numeric Rating Scale 0-10.\n* Patient needs bilateral hip replacement or has a planned THA on the contralateral hip joint in the next 24 months.\n* Patient needs knee arthroplasty or has a planned total knee arthroplasty in the next 24 months.\n* Patient has a known allergy to titanium and\u002For XLPE.\n* Patient has known metal sensitivities to cobalt chromium (CoCr).\n* Patient has a history of septic arthritis in the index joint.\n* Patient has insufficient acetabular or femoral bone stock in which good anchorage of the implants is unlikely or impossible.\n* Patient has total or partial absence of the muscular or ligamentous apparatus.\n* Patient has known moderate to severe renal insufficiency.\n* Patient has vascular insufficiency, muscular atrophy, or neuromuscular disease in either leg (based on the Investigator's judgment).\n* Patient has a deformity of the affected limb or significant anatomic variance of the affected hip.\n* Patient has an active malignancy or history of invasive malignancy within the last 5 years, except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix definitively treated more than 1 year prior to enrollment may enter the study.\n* Patient has Paget's disease, Charcot-Marie-Tooth disease, or osteomalacia.\n* Patient has an inflammatory DJD including any of its composite diagnoses: rheumatoid arthritis, systemic lupus erythematosus, pigmented villonodular synovitis, juvenile rheumatoid arthritis, and other arthritic processes of inflammatory or autoimmune etiology.\n* Patient has any condition that would interfere with self-assessment of pain, function, or quality of life (QoL) required for patient-reported outcomes during the study (based on the Investigator's judgment).\n* Patient has a Body Mass Index (BMI) of 40 or higher.\n* Patient has an active infection (e.g., hepatitis, Acquired Immune Deficiency Syndrome (AIDS), AIDS-related Complex (ARC)) that is systemic or at the site of the intended surgery.\n* Patient is currently participating in any investigational study not related to this study's preoperative or postoperative care.\n* Patient is currently pregnant or is planning to become pregnant during the study.\n* Patient is a competitive or professional athlete.","ALL","50 Years","75 Years",{"count":20,"type":21},288,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to determine if the use of the HIT Reverse Hip Replacement System is safe and effective in patients undergoing total hip replacement. We will determine whether it is safe and effective by comparing it to the control devices.",[27,28,29,30],"Degenerative Joint Disease","Osteoarthritis, Hip","Avascular Necrosis of Hip","Traumatic Arthropathy-Hip",[32],"total hip arthroplasty","RECRUITING","2026-05-07",{"date":36,"type":37},"2026-05-11","ACTUAL",{"date":39,"type":37},"2022-07-15",{"date":41,"type":21},"2035-07-15",{"name":43,"class":44},"Hip Innovation Technology","INDUSTRY",6,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100491987","observational-study-to-evaluate-long-term-outcome-in-hip-hemiarthroplasty-100491987","NCT05686278","Observational Study to Evaluate Long-Term Outcome in Hip Hemiarthroplasty","A Post-market Clinical Follow-up (PMCF) Study to Evaluate Clinical, Radiographic and Patient Reported Outcomes Following a Hip Hemiarthroplasty Surgery Using Corin Devices","Inclusion Criteria:\n\n1. Both genders.\n2. Adult subjects.\n3. Subjects clinically suitable for a hip hemiarthroplasty surgery with Corin hip devices based on physical examination, medical history and diagnosis such as: non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis in which the acetabulum does not require replacement, treatment of non-union, femoral neck and trochanteric fractures of the proximal femur, revision of failed partial hip replacements in which the acetabulum does not require replacement.\n4. The subject is willing to comply with the required follow-up visits as per protocol.\n5. The subject, or a designated trusted person in case the subject is unable to do, has signed a Patient Informed Consent Form (PICF), specific to this study, and approved by the local EC.\n\nExclusion Criteria:\n\n1. Subjects with active infection or sepsis or osteomyelitis.\n2. Subjects with unsuitable or insufficient bone support preventing proper fixation of the prosthesis.\n3. Subject with marked bone loss or bone absorption.\n4. Subject with metabolic disorders which may impair bone formation or bone quality.\n5. Subjects under guardianship.\n6. Subjects under jusicial protection\n7. Subjects in the opinion of the Investigator\u002F investigative team who will be unable to comply with study procedures (Examples: recent psychotic or mania disorders, alcohol, drug or substance abusers) and\u002For those unable for any medical or other reason to comply with study procedures\u002Fvisits.","18 Years",{"count":55,"type":21},368,"OBSERVATIONAL","This PMCF study is designed to collect safety and efficacy data on hip hemiarthroplasty surgeries with Corin BiPolar-i shell and the Oceane+ or Meije Duo femoral stem up to 10 years.",[59,60,28,29,61],"Hip Fractures","Hip Hemiarthroplasty","Femoral Neck Fractures",[63,64,59],"Hemiarthroplasty","Acetabulum","2026-03-17",{"date":67,"type":37},"2026-03-18",{"date":69,"type":37},"2023-06-29",{"date":71,"type":21},"2035-09",{"name":73,"class":44},"Corin",4,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100420387","g7-acetabular-system-with-vivacit-e-or-longevity-liner-pmcf-study-100420387","NCT04754087","G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study","Global, Multicenter, and Prospective Post-Market Clinical Follow-Up Study of the G7 Acetabular System With Vivacit-E and Longevity Highly Crosslinked Polyethylene (HXLPE) Liners & Instrumentation","Inclusion Criteria:\n\n* Patient must be a legal adult who has reached full skeletal maturity.\n* Patient must be treated for one of the following indications:\n* Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis\n* Rheumatoid arthritis\n* Correction of functional deformity\n* Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques\n* Revision procedures where other treatment or devices have failed\n* Patient must be able and willing to complete the protocol required follow-up visits.\n* Patient must be able and willing to sign the Institutional Review Board or Ethics Committee (IRB\u002FEC) approved informed consent.\n\nExclusion Criteria:\n\n* Patient presents with osteoporosis, which in the opinion of the Principal Investigator, may limit the subject's ability to support total hip arthroplasty using the study device.\n* Patient has a metabolic disorder that may impair bone formation.\n* Patient has osteomalacia.\n* Patient has distant foci of infections which may spread to the implant site or patient with infection, sepsis or osteomyelitis.\n* Patient has rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.\n* Patient has a vascular insufficiency, muscular atrophy, or neuromuscular disease\n* Patient is a prisoner.\n* Patient is a current alcohol or drug abuser.\n* Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.\n* Patient is pregnant.",true,{"count":84,"type":21},300,[24],"The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.",[88,89,29,90,28,91,92,93],"Total Hip Arthroplasty","Degenerative Joint Disease of Hip","Rheumatoid Arthritis of Hip","Osteoarthritis of Hip","Fractures, Hip","Fracture of Hip","2025-06-13",{"date":96,"type":37},"2025-06-18",{"date":98,"type":37},"2021-07-07",{"date":100,"type":21},"2033-12-31",{"name":102,"class":44},"Zimmer Biomet",11]